Elsevier

Schizophrenia Research

Volume 182, April 2017, Pages 144-145
Schizophrenia Research

Sublingual atropine in the treatment of clozapine-induced sialorrhea

https://doi.org/10.1016/j.schres.2016.10.039Get rights and content

Section snippets

Discussion

CIS is a common and bothersome side effect of clozapine (Sagy et al., 2014, Syed et al., 2008). As presented in the three cases above, CIS can occur at different clozapine doses, in various stages of treatment, and can interfere with treatment adherence. Oral anticholinergic and alpha-2 agonist medications have been used to treat CIS with variable efficacy, but can cause systemic anticholinergic side effects (i.e., constipation, urinary retention, cardiac arrhythmia)(Syed et al. 2008). These

Contributors

All four authors have contributed.

Role of funding source

None.

Conflict of interest

None.

Acknowledgments

None.

References (8)

  • C. Antonello et al.

    Clozapine and sialorrhea: a new intervention for this bothersome and potentially dangerous side effect

    J. Psychiatry Neurosci.

    (1999)
  • C. Comley et al.

    Use of atropine eye drops for clozapine induced hypersalivation

    Aust N Z J Psychiatry

    (2000)
  • R. Hinkes et al.

    Aspiration pneumonia possibly secondary to clozapine-induced sialorrhea

    J. Clin. Psychopharmacol.

    (1996)
  • F.A. Mustafa et al.

    Sublingual atropine for the treatment of severe and hyoscine-resistant clozapine-induced sialorrhea

    Afr. J. Psychiatry (Johannesburg)

    (2013)
There are more references available in the full text version of this article.

Cited by (22)

  • Oral Health Needs and Experiences of Medicaid Enrollees With Serious Mental Illness

    2018, American Journal of Preventive Medicine
    Citation Excerpt :

    In 2015, a total of 9.1 million adults on Medicaid had a diagnosed mental health condition.10 This population of Medicaid enrollees experiences numerous risks to oral health compared with the general population, including (1) use of medications that cause dry mouth or hypersalivation18–21; (2) higher rates of smoking and substance use19,20; (3) less healthy diets22; (4) overall poor physical health23; and (5) social issues, such as high rates of homelessness and poverty.18,20,23 Underutilization of dental services, especially preventive services, among individuals with serious mental illness (SMI) is another risk factor.24

  • Monitoring oral health of people in Early Intervention for Psychosis (EIP) teams: The extended Three Shires randomised trial

    2018, International Journal of Nursing Studies
    Citation Excerpt :

    Hypersalivation is also a side effect of treatment with clozapine. There are also neurological effects of first-generation antipsychotics (dystonia, dyskinesia) and second-generation antipsychotics induce more metabolic side effects like obesity or diabetes and these are linked to periodontal diseases (Fratto and Manzon, 2014; Matos Santana et al., 2017; Vancampfort et al., 2015). A meta-analysis of fifty seven studies looking at the prevalence of suboptimal oral health of people with mental illness, found a suboptimal oral health prevalence of 61% as well as highlighting the need for oral health training for mental health professionals (Matevosyan, 2010).

  • Perphenazine-induced sialorrhea successfully treated with sublingual atropine: A case report

    2019, Personalized Medicine in Psychiatry
    Citation Excerpt :

    One common pharmacologic treatment is antimuscarinics such as benztropine, trihexyphenidyl, glycopyrrolate, and atropine. Atropine sublingual drops, which have long been used for drooling in disorders such as cerebral palsy [9], have demonstrated efficacy in clozapine-induced sialorrhea [7,8,10]. Another approach is the use of a centrally-acting alpha-2 adrenergic agonist, most often clonidine, usually used as a patch to prevent rapid fluctuations in blood pressure [7,8,11].

View all citing articles on Scopus
View full text